Preclinical pharmacokinetics: An approach towards safer and efficacious drugs

Current Drug Metabolism

Volumn 7, Issue 2, 2006, Pages 165-182

  Singh, Sonu Sundd ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

CYP450 inhibition; Induction; Metabolic stability; Pharmacokinetics; Toxicokinetics

Indexed keywords

1,4 BIS(4 METHOXYPHENYL) 3 (3 PHENYLPROPYL) 2 AZETIDINONE; A 77003; A 80987; AMLODIPINE; CARBIDOPA; CELECOXIB; CHLORPROMAZINE; CILASTATIN; CLOPIDOGREL; CYTOCHROME P450; DICLOFENAC; DOCETAXEL; EZETIMIBE; FLUCONAZOLE; HALOPERIDOL; IMIPENEM; LEVODOPA; LINEZOLID; LORATADINE; LOSARTAN; MINOXIDIL; NIFEDIPINE; PACLITAXEL; PHENACETIN; PIMOZIDE; RITONAVIR; TAMOXIFEN; THROMBOXANE A2; TROGLITAZONE; UNINDEXED DRUG; CELL RECEPTOR; DRUG; PREGNANE X RECEPTOR; STEROID RECEPTOR;

AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IN VITRO STUDY; INJECTION SITE IRRITATION; LIPOPHILICITY; LIVER TOXICITY; NONHUMAN; PARKINSON DISEASE; PHLEBITIS; REVIEW; ANIMAL; DRUG INTERACTION; DRUG SCREENING; GENETICS; METABOLISM; PHARMACOKINETICS; RAT; SPECIES DIFFERENCE;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; GENETICS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; SPECIES SPECIFICITY;

EID: 33644896517     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920006775541552     Document Type: Review

References (86)

1. Armer, R. E. and Morris, I.D. (2004) Drug News Perspect. 17 (2), 143-148.
2. Kola, I. and Landis, J. (2004) Nat. Rev. 3, 711-716.
3. Li, A.P. (2004) DDT. 9, 687-693.
4. Lin, J.H.; Lu, A.Y. (1997) Drug Metab. Dispos. 49 (4), 403-449.
5. Eddershaw, P.J.; Beresford, A.P. and Bayliss, M.K. (2000) DDT. 5 (9), 409-414.
6. Park, K.B.; Kitteringham, N.R.; Maggs, J.L.; Pirmohamed, M.; Williams, D. P. (2005) Annu. Rev. Pharmacol. Toxicol. 45, 177-202.
7. Lee, W.M. (2003) N. Engl. J. Med. 349(5), 474-485.
8. Smith, K.S.; Smith, P.L.; Heady, T.N.; Trugman, J.M.; Harman, W.D.; Macdonald, T.L. (2003) Chem. Res. Toxicol. 16(2), 123-8.
9. Dieckhaus, C.M.; Thompson, C.D.; Roller, S.G. and Macdonald, T.L (2002) Chem. Biol. Interact. 142(1-2), 99-117.
10. Wilding, I.R. and Bell, J.A. (2005) DDT. 10(13), 890-894.
11. DiMasi, J.A. (2001) Clin. Pharmacol. Ther. 69, 297-307.
12. Prentis, R.A.; Lis, Y. and Walker, S.R.(1988) Br. J. Clin. Pharmacol. 25(3), 387-396.
13. DiMasi, J.A. (2002) Pharmacoeconomics 20 (3), 1-10.
14. Kerns, E.W. and Di, L. (2003). DDT. 8 (9), 316-323.
15. Jenkins, K.M.; Angeles, R.; Quintos, M.T.; Xu, R.; Kassel, D.B. and Rourick, R. A. (2004) J. Pharm. Biomed. Anal. 34, 989-1004.
16. Li, A. P (2001) DDT.6 (7), 357-366.
17. Minkel, J.R. (2003) Drug Discov. Develop. Nov, 50-54.
18. Koppal, T. (2003) Drug Discov. Develop. Nov, 28-32.
19. Plant, N. (2004) DDT. 9(7), 328-336.
20. Guidance for Industry Drug Metabolism/Drug Interaction, Studies in the Drug development Process: Studies In- vitro, Department of Health and Human Services U.S. Food and Drug Administration, Center for Drug Evaluation and Research Center For Biologics Evaluation and Research, April 1997, CLIN 3 (Website) http://www.fda.gov/cder/guidance.htm
21. Riley, R.J. and Grime, K. (2004). DDT 1(4), 365-372.
22. Bjornsson, T.D.; Callaghan, J.T.; Einolf, H.J.; Fischer, V., Lawrence Gan, Scott Grimm, John Kao, King, S.P.; Miwa, G.; Ni L.;, Kumar, G.; McLeod, J.; Scott Obach, R.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J.T.; Tweedie, D.; Vega, J.M.; Walsh, J. and Wrighton, S.A.(2003) Drug Metab. Dispos. 31, 815-832.
23. Lappin, G. and Gamer, R.C. (2003) Nat. Rev. Drug Discov. 2, 233-240
24. Wilding, I.R. and Garner, C. (2004) Good Clin. Pract. J. 11, 17-19.
25. Wilding, I.R. (2005)Use of human microdosing studies to improve the Pharmacokinetics/Bioavaliability (PK/BA)quality of new drug candidates.A practice guide.Clinical research manual Supplement 19 (Luscombe Dand Stonier, P eds. Euromeds).
26. Manitpisitkul, P. and White, R.E. (2004) DDT 9(15), 652-658.
27. White, R.E. and Manitpisitkul, P. (2001) Drug Metab. Dispos. 29(7), 957-966.
28. Christ, D.D. (2001) Drug Metab. Dispos. 29(7), 935.
29. Cox, K.A. Dunn-Meynell, K.; Korfmacher, W.A.; Broske, L.; Nomeir, A.A. Chin-Chung Lin, Cayen, M.N. and Barr, W.H. (1999) DDT. 4 (5), 232-237.
30. Sandhu, P. et al (2004) Drug Metab. Dispos. 32, 1254-1259.
31. Lappin, G. and Garner, R.C. (2004) Anal. Bioanal. Chem. 378, 356-364
32. Aberra, Fa.; Yue-Zhong, Shu.; Mingshe, Zhu.; Ronald, L.H. Roongta, V. and Humphreys, W.G. (2004) J. Med. Chem. 47 (18), 4339-4350.
33. Nassar A.E.F.; Kamel, A. M. and Clarimont, C. DDT. 9 (23), 1020-1028.
34. Benigni, R. (2004) DDT Technol. 1 (4) 457-463.
35. Park, K.B.; Kitteringham, N.R.; O'Neill, P.M. (2001) Annu. Rev. Pharmacol. Toxicol. 41, 443-470.
36. Hans-Joachim Bohm, Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Muller, K.; Obst-Sander, U. and Stahl, M. (2004) Chembio. Chem. 5, 637-643.
37. Richardson, K. (1993) DN & P. 6,299-303.
38. Ismail, F.M.D. (2002) J. Fluorine Chem. 118, 27-33.
39. Heek, M.; van France, C.F.; Compton, D.S.; McLeod, R.L.; Yumibe, N.P.; Alton, K.B.; Sybertz, E.J. and Davies, H.R. (1997) J. Pharmacol. Exp. Therap. 283, 157-163.
40. Clader, J.W. (2004) J. Med. Chem. 47, 1-9.
41. Smith, D.H.; van de Waterbeemd, H. and Walker, D.K. Pharmacokinetics and Metabolism in Drug Design, Methods and Principles in Medicinal Chemistry, Vol. 13, Wiley-VCH, Weinheim, 2001.
42. Penning, T.D.; Talley, J.J.; Bertenshaw, S.R.; Carter, J.S.; Collins, P.W.; Docter, S.; Graneto, M.J. Lee, L.F.; Malecha, J.W.; Miyashiro, J.M.; Rogers, R.S.; Rogier, D.J.; Yu, S.S.; Anderson, G.D.; Burton, E.G.; Cogburn, E.G. Anna Struneckál, Jirí Patocka, Paul Connett (2004) J. Appl. Biomed. 2, 141-150.
43. Resnati, G. (1990) Farmaco 45, 1043-1066.
44. Fried, J.; Hallinan, E.A. and Szwedo, M.J. (1984) J. Am. Chem. Soc. 106, 3871-3872.
45. Struneckál, A.; Patocka, J. and Connett, P. (2004) J. Appl. Biomed. 2, 141-150.
46. Fried, J.; Mitra, D.K.; Nagarajan, M. and Mehrotra, M.M. (1980) J. Med. Chem. 23, 234-247.
47. Mark, P.; Grillo, L.; Chiellini, G.; Tonelli, M. and Benet, L.Z. (2001) Drug Metab. Dispos. 29(9), 1210-1215.
48. Ojima, I.; Inoue, T.; Slater, J.C.; Lin, S.N.; Kuduk, S.D.; Chakravarty, S.; Walsh, J.J.; Cresteil, T.; Monsarrat, B.; Pera, P. and Bernacki, R.J. (2000) Asymm. Fluoroorg. Chem. ACS Symp. Ser. 746, 158-181.
49. Ojima, I.; Inoue, T. and Chakravarty, S. (1999) J. Fluorine Chem. 97, 3-10.
50. Antony, S.J.; Diaz-Vasquez, E. and Stratton, C.J. (2001) Natl. Med. Assoc. 93 386-391.
51. Koerts, J.; Soffers, A.E. M.F. Vervoort, J.; De Jager, A. and Rietjens, I.M.C. (1998) Chem. Res. Toxicol. 11, 503-512.
52. Dear, G.J.; Ismail, I.M.; Mutch, P.J.; Plumb, R.S.; Davies, L.H. (2000) Xenobiotica 30, 407-426.
53. Kirk, K.L.; Cantacuzene, D.; Collins, B.; Chen, G.T.; Nimit, Y. (1982) J. Med. Chem. 25, 680-684.
54. Morgan, P.; Maggs, J.L.; Page, P.C.B. and Park, B.K. (1992) Biochem. Pharmacol. 44, 1717-24.
55. Liljebris, C.; Larsen, S.D.; Ogg D.; Palazuk B.J. (2002) J. Med. Chem. 45, 1785-1798
56. Krieter, P.A.; Colletti, A.E.; Miller, R.R.; Stearns, R.A. (1995) J. Pharmacol. Exp. Ther. 273, 816-822.
57. Arrow smith, J.E.; Campbell, S.F.; Cross, P.E.; Stubbs, J.K.; Burges, R.A.; Gardiner, D.G.; Blackburn, K.J. (1986) J. Med. Chem., 29, 1696-1702.
58. Kempf, D.J.; Marsh, K.C.; Denissen, J.F.; MaDonald, E.; Vasavanonda, S S.; Flentge, C.A.; Green, B.E.; Fino, L.; Park, C.H.; Kong, X.; Wideburg, N.E.; Saldivar, A.; Ruiz, L.; Kati, W.M.; Sham, H.L.; Robins, T.; Stewart, K.D.; Hsu, A.; Plattner, J.J.; Leonard, J.M. and Norbeck, D.W. (1995) PNAS 92, 2484-2488.
59. Kumar, G.N.; Dykstra, J.; Roberts, E.M.; Jayanti, V.K.; Hickman, D.; John Uchic, Ye Yao, Surber, B.; Thomas, S. and Granneman, G.R (1999) Drug Metab. Dispos. 27, 902-908.
60. Maskalyk, J. (2002) CMAJ 167(3), 279-278.
61. Marsden, C.D. (1976) Scott. Med. J. 21, 139-148.
62. Kropp, H:; Sudenlof, J.G.; Kahan, J.S.; Kahan, F.M. and Birnbaum, J. (1980) Antimicrob. Agents Chemother. 17, 993-1000.
63. Wiedeman, P.E.; Trevillyan, J.M. (2003) Curr. Opin. Invest. Drugs 4 (4), 412-420.
64. Clarke, T.A. and Waskell, L.A. (2003) Drug Metab. Dispos. 31(1), 53.
65. Pereillo, J.M.; Maftouh, M.; Andrieu, A.; Uzabiaga, M.F.; Fedeli, O.; Savi, P.; Pascal, M.; Herbert, J.M; Maffrand, J.P. and Picard, C. (2002) Drug Metab. Dispos. 30(11), 1288.
66. Stearns, R.A.; Chakravarty, P.K.; Chen, R. and Chiu, S.H. (1995) Drug Metab. Dispos. 23(2), 207-215.
67. Wang, J.S.; Neuvonen, M.; Wen, X.; Backman, J.T. and Neuvonen, P.J. (2002) Drug Metab. Dispos. 30 (12), 1352-1356.
68. Williams, M.A. (2004) DDT. 9 (11), 478-484.
69. Shou, M. (2004) Drug Metab. Dispos. 9(15), 636-637.
70. Atkins, W.M. Lu, W.D. and Cook, D. L (2002) J. Biol. Chem. 277(36), 33258-33266.
71. Wang, R.W. Newton, D.J.; Liu, N.; Atkins, W.M.; Lu, A.Y.H. (2000) DDT. 28(3), 360-366.
72. Shou, M.; Dai, R.; Cui, D.; Kenneth R. Korzekwa, K.R.; Baillie, T.A. and Rushmore, T.A. (2001) J. Biol. Chem. 276 (3), 2256-2262.
73. Sahi, J.; Black, C.B.; Hamilton, G.A.; Zheng, X.; Jolley, S.; Rose, K.A.; Gilbert, D.; LeCluyse, E.L.; Sinz, M.W. (2003) Drug Metab. Dispos. 31, 439-446.
74. Wilson, T.M. and Kliewer, S.A. (2002) Nat. Rev. Drug Discov. 1, 259-266.
75. Bryan, G.; Matthew, R.R.; Kliewer, S.A. (2002) Annu. Rev. Pharmacol. Toxicol. 42, 1-23.
76. Xie, W.; Uppal, H.; Saini, S.P.S.; Mu, Y.; Little, J.M.; Radominska-Pandya, A.; Zemaitis, M.A. (2004) DDT. 9 (10), 442.
77. Quattrochii, L.C.; Guzelian, P.S. (2001) Drug Metab. Dispos. 29 (5), 615-622.
78. Synold, T.W.; Dussault, I.; Forman, B.M. (2001) Nat. Med. 7(5), 584-590.
79. Xie, W.; Barwick, J.L.; Downes, M.; Blumberg, B.; Simon, C.M.; Nelson, M.C.; Neuschwander-Tetri, B.A.; Brunt, E.M.; Guzelian, P.S.; Ronald (2000) Nature 406, 435-439.
80. Kong T.C. (1985) Anal. Chim. Acta 151, 193.
81. Melten, J.W.; Witter Brood, A.J.; Williams, H.J.J.; Faber, G.H. Wemer, J.; Faber, D.B. (1985) J. Pharm. Sci. 74, 692.
82. Paxton J.W.; Calder, R.L. (1985) J. Pharm. Methods 74, 692.
83. Machinist, J.M.; Kukulka, M.J.; Bopp, B.A. (1995) Clin. Pharmacokinet. 29, 34.
84. Cheng, Y.; Ho, E.; Subramanyan, B.; Jih-lie, T. (2004) J. Chromator. B. 809, 67-73.
85. Baldrick, P. (2003) DDT. 8(3), 127-133.
86. CPMP/ICH/384/95: Operational June 1995. Toxicokinetics: guidance for assessing systemic exposure in toxicology studies. Also known as ICH Topic S3A (Web site) http://www.emea.eu.int.